TCMD - NASDAQ
Tactile Systems Technology, Inc.
$24.37
-0.16%Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
At a Glance
Live SnapshotTactile Systems Technology, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Effective Tax Rate
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Tactile Systems Technology, Inc. Income Statement
TCMD • NASDAQ
| Tactile Systems Technology, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||
329.5M | 293M | 274.4M | 246.8M | 208.1M | 187.1M | 189.5M | 143.8M | 109.3M | 84.5M | 62.9M | 47.7M | 37.2M | |
GROSS PROFIT | |||||||||||||
(81.8M) | (76.3M) | (79.3M) | (70.8M) | (59.8M) | (54.3M) | (55.3M) | (41.5M) | (29M) | (22.9M) | (16.9M) | (12.7M) | (9.8M) | |
247.7M | 216.7M | 195.1M | 176M | 148.2M | 132.8M | 134.2M | 102.3M | 80.3M | 61.6M | 46M | 35M | 27.4M | |
OPERATING INCOME | |||||||||||||
(218.4M) | (194.5M) | (177.1M) | (188.7M) | (150M) | (136.4M) | (123.7M) | (99.3M) | (76.4M) | (57.3M) | (42.5M) | (31.2M) | (25M) | |
(209.9M) | (183.1M) | (169.2M) | (167.2M) | (143.6M) | (131M) | (118.4M) | (94M) | (71.3M) | (52.9M) | (38.2M) | (28.4M) | (22.6M) | |
(8.5M) | (8.8M) | (7.8M) | (7.1M) | (5.7M) | (5.3M) | (5.2M) | (5.3M) | (5.1M) | (4.5M) | (4.3M) | (2.8M) | (2.4M) | |
29.3M | 22.2M | 18M | -12.8M | -1.8M | -3.6M | 10.5M | 3M | 3.9M | 4.3M | 3.5M | 3.8M | 2.4M | |
PRE-TAX INCOME | |||||||||||||
(1M) | (2.1M) | (4.1M) | (2.8M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
2.1M | 1.3M | -2.3M | -2.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (2.5M) | (76K) | (14.4M) | (739K) | (197K) | (194K) | (486K) | (292K) | (38K) | -194K | -4K | (4K) | |
2.1M | 1.3M | -2.3M | -2.7M | -531K | 1.4M | 631K | 486K | 292K | 38K | -194K | -4K | 4K | |
31.3M | 23.5M | 15.8M | -15.5M | -2.3M | -2.3M | 11.1M | 3.5M | 4.2M | 4.3M | 3.3M | 3.8M | 2.4M | |
NET INCOME | |||||||||||||
(12.3M) | (6.5M) | -12.7M | (2.4M) | (9.5M) | -1.6M | (158K) | -3.1M | -1.7M | (1.4M) | (1.9M) | (1.7M) | -772K | |
19.1M | 17M | 28.5M | -17.9M | -11.8M | -620K | 11M | 6.6M | 5.9M | 2.9M | 1.4M | 2.1M | 3.2M |
SEC Filings
TCMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 07, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 25, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 17, 2026 | December 31, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 03, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 04, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your TCMD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.